- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.10. | OS Therapies Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.10. | OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 305 | Newsfile | New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 17.10. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 389 | Newsfile | Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation &... ► Artikel lesen | |
| 10.10. | OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate | 3 | Benzinga.com | ||
| 10.10. | OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma | 284 | Newsfile | 75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p 100% of patients who achieved 12 month event free survival achieved 2 year overall... ► Artikel lesen | |
| 09.10. | OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting | 249 | Newsfile | Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care existsRapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcoma... ► Artikel lesen | |
| 07.10. | OS Therapies to Participate in Fall 2025 Conferences and Events | 272 | Newsfile | Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and human & canine patients who participated... ► Artikel lesen | |
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 30.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | OS Therapies Updates Sequence Of OST-HER2 Regulatory Submissions, Prioritizes UK MHRA MAA Submission | 1 | RTTNews | ||
| 30.09. | OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update | 225 | Newsfile | Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meeting... ► Artikel lesen | |
| 19.09. | OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT | 250 | Newsfile | New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 12.09. | OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit | 275 | Newsfile | Clinical data from Phase 1b prostate cancer trial to be released in Q4/25Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prevention... ► Artikel lesen | |
| 03.09. | OS Therapies to Participate in Upcoming Investor Conferences in September 2025 | 287 | Newsfile | New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 02.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting | 321 | Newsfile | Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp.... ► Artikel lesen | |
| 02.09. | OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing | 416 | Newsfile | All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds to be used to accelerate OST-HER2 commercial launch preparationsNew... ► Artikel lesen | |
| 27.08. | OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025 | 385 | Newsfile | New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 26.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | OS Therapies Terminates Equity Line of Credit | 425 | Newsfile | New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 49,000 | +2,51 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| IMMUNIC | 0,672 | -0,15 % | Roth/MKM initiates Immunic stock with Buy rating on MS drug potential | ||
| PHIO PHARMACEUTICALS | 1,610 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 5,934 | +0,41 % | ANAVEX LIFE SCIENCES CORP zündet nächste Kursrakete! | ||
| ARCTURUS THERAPEUTICS | 8,670 | 0,00 % | Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA | ||
| ZEVRA THERAPEUTICS | 7,800 | -4,29 % | Zevra signals European expansion for MIPLYFFA as U.S. coverage reaches 66% following robust Q3 | ||
| PROTALIX BIOTHERAPEUTICS | 1,840 | 0,00 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics to Present at Investor Summit Virtual | CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization... ► Artikel lesen | |
| GEOVAX LABS | 0,490 | 0,00 % | GeoVax Labs files to sell 11.9M shares of common stock for holders | ||
| SCILEX | 18,680 | 0,00 % | Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November ... | ||
| MEIRAGTX | 7,650 | -0,65 % | MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology | LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 1,415 | 0,00 % | Tenaya Therapeutics GAAP EPS of -$0.12 beats by $0.03 | ||
| INVIVYD | 1,650 | 0,00 % | Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights | PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash equivalents... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 4,810 | 0,00 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End | LOS ALTOS, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,70 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCELLX | 90,23 | 0,00 % | Arcellx, Inc. - 10-Q, Quarterly Report |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,900 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.